Traditional Chinese Medicine in Treating Children With Coronavirus Disease 2019: A Scoping Review

Naifan Duan, Bin Liu, Xiaona Li, Yibai Xiong, Li Li, Yan Ma and Cheng Lu*

Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Science, Beijing, China

Coronavirus disease 2019 (COVID-19) is currently widely spread across the world. Traditional Chinese Medicine (TCM) plays an important role in the overall treatment process. As a special group of population, the treatment outcome of children with COVID-19 has attracted much attention. Our study summarizes the current situation of TCM treatment of children with COVID-19. The results showed that TCM displayed a positive role in the treatment process, and that no significant adverse reactions were found. Our findings provide analytical evidence for the efficacy and safety of TCM participation in the treatment of COVID-19 in children.

Keywords: COVID-19, children, traditional Chinese medicine, syndrome differentiation, efficacy and safety

INTRODUCTION

In the past 2 years, coronavirus disease 2019 (COVID-19) has repeatedly emerged as an acute respiratory infectious disease. Children have their own unique physiological and pathological characteristics, and they respond differently to the virus compared with adults. Studies have shown that patients with mild COVID-19 may be less likely to be seroconverted in children than in adults at the same viral load (1). It has also been shown that long-term humoral immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children last longer even after asymptomatic infection than in adults (2). At present, the emergence of SARS-CoV-2 variants has caused the increasing prevalence in children around the world (3–6). More research is urgently needed on the long-term relationship between COVID-19 and children (7). Clinicians have tried a variety of therapeutic regimens and constantly summarized the experience during the process. Corresponding treatment guidelines have been formulated around the world. Among the regimens, Traditional Chinese Medicine (TCM) is mentioned in diagnosis and treatment plans in China (8–11), and it is widely used and shows unique advantages. In March 2022, the World Health Organization (WHO) Expert Meeting on Evaluation of TCM in the Treatment of COVID-19 was held, and it was noted that participation of TCM could reduce the aggravation rate of mild and moderate patients and shorten the duration of viral shedding and hospital stay. The safety of TCM treatment is similar to that of conventional treatment (12). Currently, most studies have focused on describing the TCM efficacy evidence of COVID-19 in adults, and there is less evidence about children.

Studies have shown that children with COVID-19 have a variety of initial symptoms, some have fever and respiratory symptoms (13, 14), some have digestive tract symptoms (15, 16), and

Abbreviations: COVID-19, Coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TCM, Traditional Chinese Medicine; WHO, World Health Organization; RCT, randomized controlled trial.
some patients have no obvious clinical symptoms but only have fatigue (17). In the course of disease development, there are more changes in symptoms. TCM can flexibly respond to changes in symptoms according to syndrome differentiation. Children act as a special group of people, and a comprehensive and systematic evaluation of the efficacy of TCM is an urgent problem to be solved at present. The results can provide a reference for doctors to guide drug use and for the formulation of a TCM prevention and treatment of COVID-19 policy for children. Our study summarizes the current situation of TCM treatment of COVID-19 in children.

METHODS

Search Strategy

The following databases were searched from establishment to 2 December 2022: CNKI, Wanfang, SinoMed, PubMed, Cochrane Library, and Embase. The MeSH terms include COVID-19, children, and TCM. We also manually searched for studies that met our inclusion criteria from other sources that were not included in the aforementioned databases. Two researchers (Duan N. F. and Liu B.) independently selected eligible studies. Studies in any language were retrieved.

Inclusion and Exclusion Criteria

The inclusion criteria were as follows: (1) meeting the diagnostic criteria of COVID-19 diagnosis and treatment protocol: version 4–8 (18–22), (2) randomized controlled trials (RCTs), retrospective cohort studies, and retrospective clinical observational studies, (3) patient age < 18 years old, (4) the intervention measures are integrated Traditional Chinese and Western medicine or TCM alone, and (5) the primary outcome is clinical outcome, and the secondary outcomes can include with or without hospitalization, time to viral shedding, adverse reactions, and time to symptom resolution. The exclusion criteria were as follows: (1) guidelines, reviews, network pharmacology, and basic experimental research, (2) suspected case research, (3) no treatment regimens were described, and (4) missing primary outcome data.

Data Extraction and Risk of Bias Assessment

According to standard information extraction tables, two researchers (Duan N. F. and Liu B.) independently extracted the data. Throughout the process, disagreements were resolved by discussion or by involving another researcher (Lu C.). The basic information extracted from the articles included authors' names, publication year, published region, type of study design, date of illness onset, virus detection results, number of cases, sex, age, medical history, epidemiological history, type of clinical classification, syndrome differentiation, symptoms, tongue image, treatment regimens, course of treatment, outcome indicators, and adverse reactions. We conducted a risk of bias assessment of the included RCT studies. Two reviewers (Duan N. F. and Li X. N.) independently assessed the risk of bias in each study using the criteria outlined in the Cochrane Handbook (2019). Any disagreements were resolved by discussion or by involving another author (Lu C.). The risk of bias was assessed according to the following domains: (1) random sequence generation, (2) attrition bias, (3) allocation concealments, (4) blinding of participants and personnel, (5) blinding of outcome assessment, (6) incomplete outcome data, (7) selective outcome reporting, and (8) other biases. Each potential source of bias was graded as high, low, or unclear, providing a quote from the study report and a justification of our judgment in the “risk of bias” table. In the table, red represents high risk, yellow represents unclear risk, and green represents low risk. We also added notes in the table when information on the risk of bias was related to unpublished data or correspondence with a trial author. When evaluating treatment effects, we considered the risk of bias in studies that contributed to the outcome.

RESULTS

Search Results and Study Characteristics

A total of 558 studies were identified using the search strategy and included 72 from CNKI, 121 from Wanfang, 91 from SinoMed, 134 from PubMed, 0 from the Cochrane Library, and 140 from Embase. Of these, 218 duplicate studies were excluded, and 319 studies were excluded after abstract review. Ultimately, 21 studies involving 406 cases were included. Among these, there were 19 retrospective studies (23–41) and 2 RCTs (42, 43). The flowchart of the screening process is presented in Figure 1.

Retrospective Clinical Study

Twelve studies were published in 2020 and 7 in 2021. The distribution area covers 13 provinces in China. The age range is mainly 7–18 years old. There were 147 men and 99 women. Clinical classification was 13 asymptomatic, 133 mild, and 81 moderate types. The main symptoms were fever and cough, and some cases were accompanied by nausea and vomiting, diarrhea, constipation, and other gastrointestinal symptoms. Another part of the cases did not show clinical symptoms during the medical process. A very small number of children had a previous medical history. Detailed characteristics of the studies are presented in Table 1.

Treatment Regimens Analysis

Fifteen studies used integrated TCM and Western medicine treatment regimens, and 4 studies used TCM treatment regimens alone. TCM treatment is based on syndrome differentiation according to different case characteristics. The cases of 6
studies had damp-heat syndrome, 3 showed cold-damp syndrome, and 3 had lung/spleen Qi-Yin deficiency syndrome in the later stage of the disease. The remaining studies did not clearly specify the type of syndrome differentiation. The main symptoms of damp-heat syndrome include fever, cough, headache, chest tightness, heavy body, poor appetite, loose stool, reddened tongue, and yellow greasy tongue coating. The main symptoms of cold-damp syndrome include loose stool, reddened tongue, and yellow greasy tongue coating. The main symptoms of lung/spleen Qi-Yin deficiency syndrome include fever, cough, nasal congestion, runny nose, pale tongue, coating. The main symptoms of cold-damp syndrome include fever, cough, headache, chest tightness, heavy body, poor appetite, loose stool, reddened tongue, and yellow greasy tongue coating. The main symptoms of lung/spleen Qi-Yin deficiency syndrome include fever, cough, fatigue, pharyngoxerosis, reddened tongue, and thin tongue coating.

The most commonly used type of drug is TCM decoction. Cold-damp syndrome uses Qingfei Paidu Decoction more often. If the damp-heat syndrome is more damp than heat, Huoxiang Zhengqi Powder, Sanren Decoction, Shenling Baishu Powder are used, if the heat is more than damp, Maxing Shigan Decoction will be added. For the Lung-spleen Qi-Yin deficiency syndrome, the most commonly used medical treatment is Yufengping Powder, Shansen Maidong Decoction, and Shengmaig Powder. The commonly used Chinese patent medicines include Lianhua Qingwen capsule, Xiaoer Chaigui Tuire granules, Pudilan Xiaoyan oral liquid, etc. A part of the cases used TCM injection for adjuvant treatment.

Western medicine treatment regimens are mainly antiviral drugs combined with antibiotics and symptomatic supportive treatment according to disease situation. Among the 19 studies included, the number of antiviral drug use times is: 13 studies using interferon, 6 studies using Ribavirin, 4 studies using Arbidol, 6 studies using Lopinavir/Ritonavir, and 4 studies using Oseltamivir. The number of antibiotic use times is: 13 studies using azithromycin, 3 studies using cephalosporin antibiotics, 2 studies using penicillin antibiotics, and 1 study using vancomycin. The number of immunotherapy use times is: 3 studies using gamma globulin and 1 study using human immune globulin. The symptomatic support treatment programs include hormone therapy, regulating intestinal flora, defervescence, antiagulation, oxygen inhalation, etc. The details are presented in Table 1.

### Treatment Outcomes

The clinical outcomes of all the cases included in the 19 studies were cured and discharged. Ten studies counted the length of hospital stay, which ranged from 9.5 to 32 days. Among them, there were 6 studies using integrated traditional Chinese and Western medicine regimens, and the length of hospital stay was 15, 9.5, 21, 10.8, and 19.2, respectively. There were 4 studies using TCM regimens alone, and the length of hospital stay was 15, 9, 15, 32, and 21 days, respectively. Nine studies counted the time of viral shedding, which ranged from 1 to 32.6 days. Among them, there were 7 studies using integrated traditional Chinese and Western medicine regimens, and the time of viral shedding was 16, 1–6, 12.5, 23, 14.7, 4–21, and 7–23 days, respectively. There were 2 studies using TCM regimens alone, and the time of viral shedding was 15.2–32.6 and 19 days, respectively. One study counted the time to fever resolution, and the time was 1.76 days, and the treatment regimen was TCM treatment alone. One study counted the time of stool viral shedding, and the time was 15.5 days, and the treatment regimen was traditional Chinese and Western medicine.

In the above studies, some of the time outcome indicators were calculated in the mean value, some in the median value, and the data cannot be combined and analyzed, so the results are presented in the form of tables. The details are presented in Table 1.

### Prospective Clinical Study

The 2 studies were published in 2021 and 2022, respectively. The detailed characteristics of the studies are presented in Table 2.

One study included 100 children with damp-heat syndrome of COVID-19. The treatment group used Yishen Jianpi massage combined with Western medicine, and the control group used Western medicine alone. The observation period was from admission to discharge. After treatment, symptom remission rate was higher in the treatment group than in the control group, and there was no significant difference in fever disappearance rate and immunoglobulin levels were higher in the treatment group than in the control group. The study has shown that adding pediatric massage can shorten the course of the disease and relieve the symptoms (42).

One study included 60 children with cold-damp syndrome of COVID-19. The treatment group used thunder-fire moxibustion plus Qingfei Paidu Decoction, and the control group used Qingfei Paidu Decoction alone. After 5 days of treatment, cough disappearance rate and immunoglobulin levels were higher in the treatment group than in the control group, and there was no significant difference in fever disappearance rate. The study has shown that adding thunder-fire moxibustion can accelerate the improvement of part symptoms and improve body immunity (43).

The assessment of risk of bias (Figure 2) showed that 2 studies implemented randomized grouping. There was no mention of allocation concealment and blinding. With regard to incomplete outcome data and selective reporting, the 2 studies reported the results according to preset outcome indicators and were rated as
| Study                          | Sex | Age (Y) | Medical History | TCM Syndrome | Symptoms | Western Medicine | TCM Treatment | Outcomes | Discharged |
|-------------------------------|-----|---------|-----------------|--------------|----------|-----------------|--------------|----------|------------|
| Ge et al. (23); Hubei         | 0   | 12.5    |                 | D-H syndrome, L-S Qi-Yin deficiency syndrome | Fever, cough, headache, chest tightness, heavy body, poor appetite, loose stool | Sanren Decoction, Shenling Baizhu Powder, Maxing Shigan Decoction, Yupingfeng Powder | IFN, Ribavirin | Ceftezole | 15         |
| Yuan et al. (24); Fujian      | 50  | 38      | G6PD deficiency, Surgery of ASD repair, Hyperthyroidism, Chronic tonsillitis, Allergic rhinitis | D-H syndrome | Fever, cough, chill, sweating, nasal congestion, runny nose, headache, cough, sore throat, throat itching, dry mouth, hyposphraesia, hypogeusia, poor sleep, constipation, diarrhea | Shangjiao Xuanbi Decoction, Shengjiang Powder, Maxing Shigan Decoction, Shashen Maidong Decoction, Shengmai Powder | Herbal plaster and gargle | - | -         |
| Hu et al. (25); Jilin          | 11  | 10      |                 | D-H syndrome, C-D syndrome | No symptoms, cough, fever, diarrhea, bitter mouth, pharyngeal discomfort, nasal congestion and runny nose | Hanshiyi Decoction, Hanshi Zufei Decoction, QFPD Decoction, Xuanfei Baidu Powder, Wenfei Huashi Decoction, Jieji Qingre Decoction, Pingwei Powder, Wenbu Pishen Decoction | Xi yanzhong, Xuebijing Injection, Arbidol, Ribavirin | Ceftriaxone sodium | 16±7.19 | Yes       |
| Liu et al. (26); Shanxi        | 0   | 8 (7–9) |                 | C-D syndrome | Cough phlegm | QFPD Decoction | IFN, LPV/r | - | -         |

(Continued)
| Study                        | Sex | Age (Y) | Medical history | Type | TCM syndrome | Symptoms | TCM | Western medicine | Outcomes | Dis charged |
|-----------------------------|-----|---------|-----------------|------|--------------|----------|-----|-----------------|----------|-------------|
| Luo et al. (27); Henan       | 0   | 3       | 6 (0.5–4)       | –    | –            | –        | –   | –               | –        | –           |
| Shang et al. (28); Shanghai  | 1   | 0       | 7               | –    | 0            | 0        | 1   | D-H syndrome, L-S Qi-Yin deficiency syndrome | Fever, chills, light cough, nausea | – | IFN, LPV/r | – | 21 | Yes |
| Chen et al. (29); Hubei      | 3   | 4       | 8 (2.6–14)      | 2 cases | 2 | 0 | 5 | Fever 4, cough and sputum 5 | TCM Decoction | – | – | IFN | – | – | – | – | Yes |
| Chen et al. (30); Hubei      | 25  | 7       | 6.9 (0.2–15.1)  | Surgery of ASD repair 1, Ophthalmic strabismus surgery 1, ALL 1 | 0 | 30 | 2 | Yedu Yudei Syndrome | TCM Decoction | – | – | Arbidol | – | – | – | – | Yes |
| Si et al. (31); Guizhou      | 1   | 0       | 13              | –    | 0            | 1        | 0   | C-D syndrome | Mahuang Jiatu Decoction, Huoxiang Zhengqi Powder, Shengliang Powder | – | – | – | – | Symptomatic support treatment | 13 | – | – | Yes |
| Yang et al. (32); Yunnan     | 4   | 1       | 7.5 ± 5.2       | –    | 2            | 2        | 1   | Cough 1, pharyngitis, discomf ort 1, myalgia 1 | QFPD Granule, Qingyun Jiere Decoction, Xuantie Baidu Decoction | – | – | – | – | Symptomatic support treatment | 15 | – | 15.2 ± 4.4 | Yes |

(Continued)
| Study | Sex | Age (Y) | Medical history | Type | TCM syndrome | Symptoms | TCM | Western medicine | Outcomes | Dis charged |
|-------|-----|---------|-----------------|------|--------------|----------|-----|-----------------|----------|-------------|
|       |     |         |                 |      |              |          |     |                 |          |             |
|       |     |         |                 |      |              |          |     |                 |          |             |
|       |     |         |                 |      |              |          |     |                 |          |             |
| Ji et al. (33); Hubei | 3 | 1 | 0.9 | (0.76–10) | – | 0 | 1 | 3 | – | Fever 2, cough 1, nasal congestion 1, short of breath 1 | TCM Decoction | Maxing Shigan Decoction, Shi Gan Decoction, Xuehua Decoction, Wu Ling Powder | – | – | IFN, Arbidol, Oseltamivir | Azithromycin | Human immune globulin, Spleen amino peptide, Budesonide, Magnesium isoglycyrrhiza, Prototype glutathione, High-dose vitamin C | 15 | – | – | Yes |
| Zhan and Bai (34); Hubei | 3 | 3 | 8.5 | (0.5–11) | – | 1 | 4 | 1 | – | Fever 4, cough 3, sore throat 3, sneezing 1 | TCM Decoction | Bairui Granule, LHQW Capsule, Fufang Yuxingcao syup | Tameqing Injection | IFN | Potassium amoxicillin-clavulanate, Piperacillin sodium tazobactam, Cephalosporins, Norvancomycin, Azithromycin | Sodium fructose diphosphate, Gammaglobulin, Ibuprofen, Oxygen inhalation, Atomization, Adjusting of intestinal flora | – | – | 1–6 | Yes |
| Tian et al. (35); Tianjin | 2 | 0 | 9.5 | (9–10) | – | 0 | 0 | 2 | – | Fever 2, cough 2, fatigue 1, epistaxis 1, dry stool 1 | Huoxiang Zhengqi Powder, Yin Qiao Powder, Maxing Shigan Decoction, Sanren Decoction | – | – | IFN | – | – | – | 12.5 | Yes |
| Hu et al. (36); Hunan | 7 | 2 | 3.9 ± 3.7 | – | 0 | 9 | – | Fever, cough, headache, dizziness, poor tolerance | COVID-19 Prevention 2 Decoction | LHQW Capsule | – | IFN, Paramivir, Arbidol, Oseltamivir, LP/vr | Cefazidine | Methyl prednisolone, Human immunoglobulin | 10.8 ± 6.5 | – | – | Yes | (Continued) |
| Study            | Sex | Age (Y) | Medical history               | Type               | TCM syndrome | Symptoms                                                                 | TCM | Western medicine | Outcomes | Dis charged |
|------------------|-----|---------|-------------------------------|--------------------|--------------|---------------------------------------------------------------------------|-----|------------------|----------|-------------|
|                  | M   | F       |                               |                    |              | Asymptomatic                                                             |     |                  |          |             |
| Chen et al.      | 1   | 0       | 7                             | —                  | 1            | 0                           | 0   | —                | Asymptomatic Zhengyang Decoction, QFPD Decoction, Toujie Qwen Decoction | —   | —               | IFN, LPV/r, Ribavarin | —   | 23           | Yes       |
|                  |     |         |                               | —                  | 0            | 6                           | 5   | —                | —               | —           | —              | 10–29     | —              | 7–27(14.7±7.2) | Yes |
| He et al.        | 6   | 5       | 5.5 (1.8–10)                  | Hepatic insufficiency after BA 1 | 0            | 6                           | 5   | —                | —               | —           | —              | —         | 7–28(15.5±7) | Yes       |
|                  |     |         |                               | —                  | 1            | 2                           | 1   | —                | Xuefan Shaoyang Syndrome | —   | —              | IFN, Ribavarin | —   | 4–10(2, 3); 21 | case 4   |
|                  |     |         |                               | —                  | 2            | 8                           | 11  | —                | Fever 3, cough 3, sore throat 1, fatigue 2 | —   | —              | —              | —         | —              | 7–23      | Yes          |
| Liu et al.       | 1   | 0       | 1.92                          | —                  | 0            | 0                           | 1   | —                | Diarrhea             | —   | —              | —              | —         | —              | 21        | Yes          |

- "M," male; "F," female; "Y," year; "D," day; "TCM," Traditional Chinese Medicine; "CPMs," Chinese patent medicines; "G6PD deficiency," glucose-6-phosphate dehydrogenase deficiency; "Surgery of ASD repair," surgery of atrial septal defect repair; "ALL," acute lymphoblastic leukemia; "Hepatic insufficiency after BA," hepatic insufficiency after biliary atresia; "D-H syndrome," damp-heat syndrome; "L-S Qi-Yin deficiency syndrome," Lung/spleen Qi-Yin deficiency syndrome; "C-D syndrome," cold-damp syndrome; "IFN," interferon; "LPV/r," Lopinavir/Ritonavir; "LHQW Capsule," Lianhua Qingwen capsule; "QFPD Decoction," Qingfei Paidu decoction; "—," not mentioned in the original study.
### TABLE 2 | Characteristics of 2 randomized control trials (RCTs) on children with COVID-19.

| Study          | Syndrome                  | Sex (M/F) | Age (Y) | Cases Type (Mild/Moderate) | Treatment | Period (D) | Outcomes |
|----------------|---------------------------|-----------|---------|---------------------------|-----------|------------|----------|
| Li (43)        | Cold-damp syndrome       | 17/13; 15/15 | 6.69 ± 2.37/ 9.23 ± 2.25 | 30/30; 9/21 | Thunder-fire moxibustion plus Qingfei Paidu Decoction/Qingfei Paidu Decoction | 5 days | 83%/80% The T was lower than C (P < 0.01) | No significant difference (P > 0.05) | The T was higher than C (P < 0.01) | No significant difference (P > 0.05) | No ADRs |
| Zhan et al. (42) | Damp-heat syndrome | 31/19; 29/21 | 4.23 ± 3.15/ 5.33 ± 3.31 | 50/50 | Yishen Jianpi massage combined with western medicine/western medicine | From admission to discharge | - The T was lower than C (P < 0.05) | - - - - | (3.76 ± 2.21)/(4.06 ± 2.18) | No ADRs |

*M,* male; *F,* female; *Y,* year; *D,* day; *T,* treatment group; *C,* control group; *ADRs,* adverse reactions; *−−−−,* not mentioned in the original study.

### DISCUSSION

According to the analysis of the above studies, TCM has a high participation rate in the treatment of COVID-19 in children. The external treatment methods also displayed their unique advantages. No obvious adverse effects appeared during the treatment process. The external treatment rate in the treatment of COVID-19 in children is high.

COVID-19 is a viral infectious disease. The survival of SARS-CoV-2 is related to environmental temperature and humidity. Take the Qinling Mountains-Huaihe River as the dividing line between the north and the south of China as an example. The Qinling Mountains-Huaihe River is the dividing line between the warm temperate climate and the subtropical climate. Due to climatic differences, temperature and humidity are higher in the south than in the north. Therefore, it can lead to different outcomes.

The above two studies only described the random number table method. No blinding methods and allocation concealment methods were mentioned. We contacted the corresponding author by telephone and email to seek a detailed study process without a response. Therefore, the results of the two randomized controlled studies have a lower evidence level.

In the future, we proposed to improve the randomization method and implement double-blinded methods to further improve the quality of the study.

**FIGURE 2 | Assessment of risk of bias in 2 trials.**

- **Random sequence generation (selection bias)**
- **Allocation concealment (selection bias)**
- **Blinding of participants and personnel (performance bias)**
- **Blinding of outcome assessment (detection bias)**
- **Incomplete outcome data (attrition bias)**
- **Selective reporting (reporting bias)**
- **Other bias**
CONCLUSION

At present, TCM is widely used in treatment of children with COVID-19, and no obvious adverse reactions have occurred. Application of TCM is a positive option in clinical practice. However, most of the current studies are retrospective clinical observational studies, and the randomized controlled studies have lower levels of evidence. More high-level evidence is still needed to verify the effectiveness and safety of TCM treatment for COVID-19 in children.

AUTHOR CONTRIBUTIONS

CL, ND, and BL conceived and designed the review. ND, XL, and BL wrote the initial draft. YX, YM, and LL were responsible for literature checking and result discussion. All authors contributed to the final version of the manuscript.

FUNDING

This study was supported by the Innovation Team and Talents Cultivation Program of the National Administration of Traditional Chinese Medicine (No. ZYYCXTD-D-202005), the Fundamental Research Funds for the Central Public Welfare Research Institutes (Nos. Z0653 and Z0727), and the National Key R&D Program of China (No. 2020YFE0205100).
REFERENCES

1. Toh ZQ, Anderson J, Mazarakis N, Neelam M, Higgins RA, Rautenbacher K, et al. Comparison of seroconversion in children and adults with mild COVID-19. JAMA Netw. Open. (2022) 5:e221313. doi: 10.1001/jamanetworkopen.2022.1313.

2. Renk H, Dulovic A, Seidel A, Becker M, Fabricius D, Zernickel M, et al. Robust and durable serological response following pediatric SARS-CoV-2 infection. Nat Commun. (2022) 13:128. doi: 10.1038/s41467-021-27595-9

3. Zhang J, Wang Y, Fan W, Hu BF, Liu YP, Yuan Y, et al. Why omicron made children hardest hit. Glob Times. (2022) 7. doi: 10.28378/n.cnki.hqsb2022.003566

4. Marks KJ, Whitaker M, Agathis NT, Anglin O, Milucky J, Patel K, et al. Hospitalization of infants and children aged 0-4 years with laboratory-confirmed COVID-19-COVID-NET, 14 states, March 2020-February 2021. MMWR Morb Mortal Wkly Rep. (2022) 71:429–36. doi: 10.15585/mmwr.mm7111e2

5. Nicolette VC, Rodrigues PT, Fernandes A, Corder RM, Tonini J, Buss LF, et al. Epidemiology of COVID-19 after emergence of SARS-CoV-2 gamma variant, Brazilian amazon, 2020-2021. Emerg Infect Dis. (2022) 28:709–12. doi: 10.3201/eid2803.211193

6. Chun JY, Jeong H, Kim Y. Age-varying susceptibility to the delta variant (B.1.617.2) of SARS-CoV-2. JAMA Netw. Open. (2022) 5:e2223046. doi: 10.1001/jamanetworkopen.2022.3064.

7. Nature. Long COVID and kids: more research is urgently needed. Nature. (2020) 602:183. doi: 10.1038/d41586-022-00334-w

8. Gao Y, Shi SZ, Liu P, Lv BW, Yang FW, Zhang JH, et al. Comprehensive analysis of diagnosis and treatment strategies for pediatric corona virus disease 2019. Chin J Clin Exp Biol. (2020) 37:22–30.

9. National Administration of Traditional Chinese Medicine. TCM diagnosis and treatment program for COVID-19 children in Tianjin (trial first 1). Tianjin J Trad Chin Med. (2022) 39:139–46.

10. General Office of National Health Commission of the People's Republic of China. Diagnosis and treatment plan for COVID-19 (trial version 9). Int J Epidemiol Infect Dis. (2022) 17:481–7.

11. Xinhua News Agency. COVID 19 in children: gastrointestinal, hepatobiliary and pancreatic characteristics of seven children with coronavirus disease 2019. Chin J Pediatr Pharm. (2020) 30:261–3.

12. Fatheha K, Hassan MN, Mazumder MW, Benzamim M, Ahmed M, Islam MR, et al. COVID 19 in children: gastrointestinal, hepatobiliary and pancreatic manifestation. Myymensingh Med J. (2021) 30:570–9.

13. Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. National Academy Press, Washington, DC. 1997-2000.

14. Wang J, Yuan X. Digestive system symptoms and function in children with COVID-19: a meta-analysis. Medicine (Baltimore). (2021) 100:e23597. doi: 10.1097/MD.00000000000123597

15. Zhu JY, Pang JL, Zhong ZM, Ji P, Li HY, Zhang JF. Clinical features of children with COVID-19: a meta-analysis. Lab Med Clin. (2021) 18(3):312–7.

16. National Health Commission of the PRC, National Administration of Traditional Chinese Medicine. Diagnosis and Treatment Plan for COVID-19 (Trial Version 4). (2020). Available online at: https://www.gov.cn/zhengce/content/2020-03/04/content_5496188.htm

17. Diagnosis. Diagnosis and treatment plan for COVID-19 (trial version 5). J Qilu Med. (2020) 35:2426–26.

18. Diagnosis. Diagnosis and treatment plan for COVID-19 (trial version 6). Tianjin Sci Technol. (2020) 37:446.

19. Diagnosis. Diagnosis and treatment plan for COVID-19 (trial version 7). China Med. (2020) 15:801–5.

20. Diagnosis. Diagnosis and treatment plan for COVID-19 (trial version 8). Chin J Clin Infect Dis. (2021) 14:81–8.

21. Ge JL, Liu X, Xu WY, Xiao K. Clinical application of “Pei Tu Sheng Jin” method in the rehabilitation of TCM in the recovery stage of children’s COVID-19. China J Ethnomed Ethnopharm. (2021) 30:95–9.

22. General Office of National Health Commission of the People's Republic of China. Diagnosis and treatment plan for COVID-19 (trial version 8). Chin J Clin Infect Dis. (2021) 14:81–8.

23. Chen Y, Shen L, Wang C, Fan R, Jiang YC. Epidemiological and clinical characteristics of seven children with coronavirus disease 2019. Chin J Exp Clin Virol. (2021) 35:15–7.

24. Chen R, Tang JQ, Jiang ZX, Chen H, Xiong XL. Clinical research of 32 children with coronavirus disease 2019 in Hubei Province. Chin J Integr Trad Western Med Intern Crit Care. (2021) 28:99–101.

25. Hu SD, Shi L, Wang T, Xu YN, Wang X, Liu QH, et al. An analysis of the clinical characteristics and TCM syndrome differentiation and treatment of children with COVID-19 in Tonghua city. J Ethn Chin Med. (2021) 41:1041–5.

26. Liu N, Wang DT, Zhou LG, Li SQ, Li TQ. Qingfei detoxification decoction combined with western medicine for symptomatic treatment of 2 children with new coronavirus infection. Asia Pac Trad Med. (2021) 17:83–5.

27. Luo SY, Zhou CC, Zhang YH, Huang HT, Yang HH, Cheng YB, et al. Three child cases of COVID-19 in Henan province: a clinical analysis. Chin J Clin Infect Dis. (2020) 13:109–12.

28. Shang FN, Huang YD, Lu JM, Zhu YQ, Zhu L, Li ZP, et al. Clinical pharmaceutical care and interpretation of children with COVID-19. Chin J Pharm. (2020) 55:773–6.

29. Chen Y, Shen L, Wang C, Fan R, Jiang YC. Clinical characteristics and diagnostic criteria of local COVID-19 cases of adults and children in Ruili City, Yunnan Province. Chin J Ethnopharm. (2021) 16:338–43.

30. Ji TY, Chen QJ, Chen FC, Huang LJ, Chen SJ, Lv MZ, et al. Clinical characteristics and drug therapy of 4 cases of children with coronavirus disease 2019. J Pediatr Pharm. (2020) 26:24–7.

31. Yang Y, Wei XX, Zheng R, Yang X, Duan HX, Yin ZQ. Analysis of epidemiological and clinical characteristics of local COVID-19 cases of adults and children in Ruili City, Yunnan Province. Chin J Ethnopharm. (2021) 16:338–43.

32. Zhan H, Bai SX. Clinical characteristics, diagnosis and treatment of novel coronavirus pneumonia in children. J Pediatr Pharm. (2020) 39:224–8.

33. Tian Y, Ma ZR, Bi YY, Li XM, Fan S, Su LS. Two cases of COVID-19 in children were treated with integrated traditional Chinese and Western medicine. Chin J Integr Trad Western Med. (2020) 40:1521–3.

34. Hu GH, Yu ZL, Liu F, Yi XY, Li Q, Chu Z. Clinical characteristics of SARS-CoV-2 infection in children in Zhuzhou city. J Humoral Natur Med (Sci). (2020) 17:42–5.

35. Zhan Q, Liu C, Sang G, Lin FJ, Lou Y, Li XM. Clinical research on the medical observation. Jishen Jianpi Massage methods treatment of COVID-19 children under medical observation. Zhejiang J Integ Trad Western Med. (2021) 31:841–4.
43. Li C. The treatment of thunder-fire moxibustion combined with Qingfei Paidu decoction is in line with the clinical efficacy of COVID-19 with cold-damp syndrome in children. Chin J Clin Ration Drug Use. (2022) 15:32–5.
44. Joonaki E, Hassanpouryouzbazan A, Heldt CL, Arego O. Surface chemistry can unlock drivers of surface stability of SARS-CoV-2 in a variety of environmental conditions. Chem. (2020) 6:2135–46. doi: 10.1016/j.chempr.2020.08.001
45. Xu R, Rahmendah H, Gupta M, DiGennaro C, Ghaffarzadegan N, Amini H, et al. Weather, air pollution, and SARS-CoV-2 transmission: a global analysis. Lancet Planet Health. (2021) 5:e671–80. doi: 10.1016/S2542-5196(21)00202-3
46. Niu L, Liang WG, Wang X, Mu YS, Wang JY, Wu D, et al. Analysis of factors affecting virus survival on object surface and in air. Res Environ Sci. (2020) 33:1589–95.
47. Xiong YB, Yan L, Li XN, Duan NF, Lin L, Lu C, et al. Pattern classification of traditional Chinese medicine and precision medicine: a narrative review. Longhua Chin Med. (2021) 4:38. doi: 10.21037/lcm-21-14
48. Yavari M. Hot and cold theory, the path towards personalized medicine. Adv Exp Med Biol. personalized medicine. Adv Exp Med Biol. (2021). 1343:1–3.
49. Yang J. Study on the effective parts of *Bupleurum-Scutellaria baicalensis* on antipyretic and its compatibility mechanism. Beijing Univ Chin Med. (2012) 10:67–9.
50. Zhu HY, Han L, Shi XL, Wang BL, Huang H, Wang X, et al. Baicalin inhibits autophagy induced by influenza A virus H3N2. Antiviral Res. (2015) 113:62–70.
51. Zhou H. Material basis and mechanism of action about clearing heat of plaster. China J Chin Med. (2015) 30:860–2. doi: 10.1016/j.antiviral.2014.11.003
52. Cao XQ, Li JA, Yang XH. Research progress of Chinese herbal medicine and its active components with warm in nature in antiviral therapy. Asia Pac Med Trad. (2021) 17:194–8.
53. Zhang T, Chen D. Anticomplementary principles of a Chinese multiherb remedy for the treatment and prevention of SARS. Ethnopharmacology. (2008) 117:351–61.
54. Xu JH, Cao HR, Chen YX. Effect of Herba epidendraceae or honey-fried herba epidendraceae alone on airway inflammation of asthmatic rats. J N Chin Med. (2014) 46:197–9. doi: 10.1016/j.jep.2008.02.012
55. Liu R, Wu ZQ, He M, Que CT, Yang J, Zeng N. Effects of volatile oil from cinnamon ramus and cinnamaldehyde on cytokines and T cell subsets in H1N1-infected mice. Chin J Exp Trad Med Formulae. (2015) 21:139–43.
56. Cao L, Xu BP, Liu G, Zhu CM, Yu H, Zhong W, et al. Expert consensus on diagnosis and treatment of influenza in children (2015 edition). Chin J Appl Clin Pediatr. (2015) 30:1296–303.
57. WHO. Global Accelerated Action for the Health of Adolescents (AA-HA!): Guidance to Support Country Implementation. Geneva: WHO (2017).
58. Wang WP. *Pediatrics*. 9th ed. Beijing: People’s Medical Publishing House (2019). p. 2–3.
59. Chen ZM, Fu JF, Shu Q, Wang W, Chen YH, Hua CZ, et al. Diagnosis and treatment recommendation for pediatric COVID-19 (the second edition). J Zhejiang Univ Med Sci. (2020) 49:139–46.
60. Bin ST, He WJ, Tan L, Li M, Zhang Q, Wang LL, et al. Comprehensive interpretation of the guidelines for the diagnosis and treatment of COVID-19 (second edition) and the COVID-19 diagnosis and treatment plan (trial version 6). J Modern Med Health. (2020) 36:3018–21.
61. Fang F, Luo XP. Facing the pandemic of 2019 novel coronavirus infections: the pediatric perspectives. Chin J Pediatr. (2020) 58:81–5.
62. Wu MJ, Tang CL, Zhang M, Ding DJ, Li R, Luo WZ, et al. Progress in clinical research of external methods on COVID-19. J Pract Trad Chin Med. (2021) 37:321–5.
63. Wang YG, Sun WQ, Zhan Q, Healthcare Quality Certification Commission [HQCC], Expert Group of Chinese Infantile Tuina Standardization Construction and Certification Committee. Expert consensus on children Tuina intervention with coronavirus disease 2019 in children (first edition). Tianjin Trad Chin Med. (2020) 37:1114–18.
64. He YJ, Song BQ, Yang LY, Zhang YL, Liu WA. Discussion on scientific basis of acupuncture prevention and treatment of novel coronavirus pneumonia from “inflammatory storm” theory. World Sci Technol Modern Trad Chin Med. (2020) 22:706–9.
65. Gu XJ, Jiang W, Zhang ZJ, Li ZY, Song P, Jiang ZY. Entry point and strategy analysis of assistance of TCM for combating COVID-19 in overseas countries. Chin J Libr Inf Sci Tradit Chin Med. (2020) 44:1–4. doi: 10.3969/j.issn.2095-5707.2020.03.001
66. Wang JL, Guo SX, Li JZ, Chen G. A study on TCM reports by six English mainstream media under the background of the COVID-19 epidemic. Future Commun. (2021) 28:16–31.

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The reviewer HT declared a shared affiliation with the authors at the time of review.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Duan, Liu, Li, Xiong, Li, Ma and Lu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.